• Home
  • NEW DAY MEDICINE
  • 4 (66) 2024
  • 152 -4 (66) 2024 - Kan N.G., Ibadullaeva N.S. - IDENTIFICATION OF CHEMOKINES AND CYTOKINES ASSOCIATED WITH COVID-19 SEVERITY

152 -4 (66) 2024 - Kan N.G., Ibadullaeva N.S. - IDENTIFICATION OF CHEMOKINES AND CYTOKINES ASSOCIATED WITH COVID-19 SEVERITY

IDENTIFICATION OF CHEMOKINES AND CYTOKINES ASSOCIATED WITH COVID-19 SEVERITY

Kan N.G. - The Research Institute of Virology of the Republican specialized scientific practical medical center of epidemiology, microbiology, infectious and parasitic diseases, Uzbekistan

Ibadullaeva N.S. - The Research Institute of Virology of the Republican specialized scientific practical medical center of epidemiology, microbiology, infectious and parasitic diseases, Uzbekistan

Khikmatullayeva A.S. - The Research Institute of Virology of the Republican specialized scientific practical medical center of epidemiology, microbiology, infectious and parasitic diseases, Uzbekistan

Turabova N.R. - The Research Institute of Virology of the Republican specialized scientific practical medical center of epidemiology, microbiology, infectious and parasitic diseases, Uzbekistan

Raximova V.Sh. - Center for the development of professional qualification of medical workers, Uzbekistan

Resume

This article provides information on the study of the relationship of chemokines (CXCL10/IP-10, CXCL9/MIG, CCL17/TARC) and cytokines (IL28B, IL-6) with the severity of COVID-19. A study of the levels of chemokines and cytokines showed a significant increase in the levels of CXCL9/MIG and IL-6 in patients with severe/extremely severe COVID-19. The chemokine CXCL9/MIG and the cytokine IL-6 can be used as biomarkers to assess the clinical status of COVID-19 patients along with other clinical data.

Keywords: COVID-19, SARS-CoV-2, chemokines, cytokines.

First page

835

Last page

839

For citation: Kan N.G., Ibadullaeva N.S., Khikmatullayeva A.S., Turabova N.R., Raximova V.Sh. - IDENTIFICATION OF CHEMOKINES AND CYTOKINES ASSOCIATED WITH COVID-19 SEVERITY//New Day in Medicine 4(66)2024 835-839 https://newdayworldmedicine.com/en/article/3758

List of References

  1. COVID-19 coronavirus pandemic. Available: https://www.worldometers.info/coronavirus/.
  2. Wang Y., Wang Y., Chen Y., Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID‐19) implicate special control measures // J Med Virol. 2020;92:568-576.
  3. Wu Z., McGoogan J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention // JAMA. 2020 Apr 7;323(13):1239-1242.
  4. Verity О., Okell L.C., Dorigatti I., Winskill P. et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis // Lancet Infect Dis. 2020;20:669-677.
  5. Sanyaolu A., Okorie C., Marinkovic A., Patidar R. et al. Comorbidity and its Impact on Patients with COVID-19 // SN Comprehensive Clinical Medicine. 2020;2:1069-1076.
  6. Channappanavar R., Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology // Semin Immunopathol. 2017; 39:529-539.
  7. Coperchini F., Chiovato L., Croce L., Magri F., Rotondi M. The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system // Cytokine Growth Factor Rev. 2020;53:25–32.
  8. Callahan V., Hawks S., Crawford M.A., Lehman C.W. et al. The Pro-Inflammatory Chemokines CXCL9, CXCL10 and CXCL11 Are Upregulated Following SARS-CoV-2 Infection in an AKT-Dependent Manner // Viruses. 2021;13(1062):1-18.
  9. Moustafa N.M., Mohamed R.A., Elsaid R.G., Mahmoud F.M. Diagnostic Value of Serum Level of Interleukin 33 (IL-33), C-C Motif Chemokine Ligand 17 (CCL17) and Interferon Gamma Inducible Protein-10 (IP-10) in Coronavirus Disease 2019 (COVID-19) Patients // Egyptian Journal of Medical Microbiology. 2022;31:23-30.
  10. Sugiyamа M., Kinoshita N., Ide S., Nomoto H. et al. Serum CCL17 level becomes a predictive marker to distinguish between mild/moderate and severe/critical disease in patients with COVID-19 // Gene. 2021;766:145145.
  11. Tufa A., Gebremariam T.H., Manyazewal T., Getinet T. et al. Inflammatory mediators profile in patients hospitalized with COVID-19: A comparative study // Frontiers in Immunology. 2022;13:964179.
  12. Hadjadj J., Yatim N., Barnabei L., Corneau A. et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients // Science. 2020;369:718-724.
  13. Blanco-Melo D., Nilsson-Payant B.E., Liu W.C., Uhl S. et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 // Cell. 2020;181:1036-1045.
  14. Aziz M, Rawish F, Ragheb A. Elevated interleukin-6 and severe COVID-19: a meta-analysis // J Med Virol. 2020;92:2283–2285.
  15. Broman N., Rantasärkkä K., Feuth T., Valtonen M. et al. IL-6 and other biomarkers as predictors of severity in COVID-19 // Annals of medicine 2021;53(1):410-412.
  16. Cruz A.S, Mendes-Frias A., Oliveira A.I, Dias L., et al. Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia // Frontiers in Immunology. 2021;12:613422.

    file

    download